Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYXNASDAQ:BBLGNASDAQ:CTSONASDAQ:EDAP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$1.92+12.0%$1.37$0.76▼$2.06$73.35M1.2179,071 shs38,379 shsBBLGBone Biologics$5.87+10.7%$4.60$3.42▼$25.50$3.23M0.75235,382 shs50,177 shsCTSOCytosorbents$1.18+1.4%$0.98$0.70▼$1.61$74.19M1.05147,070 shs86,056 shsEDAPEDAP TMS$1.71+0.3%$1.83$1.26▼$5.46$63.75M0.0197,692 shs1,040 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical0.00%-0.29%+14.77%+35.71%+25.74%BBLGBone Biologics0.00%-0.57%-0.57%-0.57%-41.28%CTSOCytosorbents0.00%+8.41%+38.06%+17.95%+54.05%EDAPEDAP TMS0.00%-3.95%-10.53%-22.37%-67.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical2.6399 of 5 stars0.05.00.04.22.91.70.6BBLGBone Biologics1.0023 of 5 stars0.05.00.00.01.20.01.3CTSOCytosorbents1.5531 of 5 stars3.52.00.00.01.20.00.6EDAPEDAP TMS1.8302 of 5 stars3.23.00.00.00.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/ABBLGBone Biologics 0.00N/AN/AN/ACTSOCytosorbents 3.00Buy$5.50372.10% UpsideEDAPEDAP TMS 2.33Hold$8.50394.19% UpsideCurrent Analyst Ratings BreakdownLatest BBLG, CTSO, EDAP, and APYX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/15/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.005/15/2025EDAPEDAP TMSPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/2/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/4/2025EDAPEDAP TMSJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$8.00 ➝ $2.004/3/2025CTSOCytosorbentsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.004/1/2025CTSOCytosorbentsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/28/2025EDAPEDAP TMSPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.503/28/2025EDAPEDAP TMSHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$48.10M1.44N/AN/A$0.38 per share4.82BBLGBone BiologicsN/AN/AN/AN/A$8.39 per shareN/ACTSOCytosorbents$35.60M2.05N/AN/A$0.20 per share5.83EDAPEDAP TMS$69.18M0.93N/AN/A$1.18 per share1.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.55N/AN/AN/A-42.37%-156.85%-31.92%8/6/2025 (Estimated)BBLGBone Biologics-$4.11MN/A0.00N/AN/AN/A-130.21%-119.39%8/8/2025 (Estimated)CTSOCytosorbents-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/12/2025 (Estimated)EDAPEDAP TMS-$20.58M-$0.62N/AN/AN/A-34.45%-51.42%-26.43%8/27/2025 (Estimated)Latest BBLG, CTSO, EDAP, and APYX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025EDAPEDAP TMS-$0.16-$0.20-$0.04-$0.20$16.56 million$16.37 million5/14/2025Q1 2025CTSOCytosorbents-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million5/12/2025Q1 2025BBLGBone Biologics-$2.88-$1.92+$0.96-$0.32N/AN/A5/8/2025Q1 2025APYXApyx Medical-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 million3/31/2025Q4 2024CTSOCytosorbents-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 million3/27/2025Q4 2024EDAPEDAP TMS-$0.11-$0.05+$0.06-$0.05$20.83 million$22.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/ABBLGBone BiologicsN/AN/AN/AN/AN/ACTSOCytosorbentsN/AN/AN/AN/AN/AEDAPEDAP TMSN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical3.215.454.64BBLGBone BiologicsN/A12.6012.60CTSOCytosorbents0.982.612.30EDAPEDAP TMS0.101.741.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%BBLGBone Biologics34.30%CTSOCytosorbents32.87%EDAPEDAP TMS62.74%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical16.80%BBLGBone Biologics6.10%CTSOCytosorbents7.30%EDAPEDAP TMS0.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.79 million31.45 millionOptionableBBLGBone Biologics2550,000512,000Not OptionableCTSOCytosorbents22062.61 million58.04 millionOptionableEDAPEDAP TMS23037.39 million37.31 millionOptionableBBLG, CTSO, EDAP, and APYX HeadlinesRecent News About These CompaniesEdap Tms (NASDAQ:EDAP) & Precision Optics (NASDAQ:POCI) Head to Head SurveyJune 16, 2025 | americanbankingnews.comEDAP TMS at Jefferies Conference: Strategic Shift to HIFU TherapyJune 7, 2025 | investing.comedap tms sa announces shareholder meeting for june 2025June 5, 2025 | investing.comEdap Tms S.A. (NASDAQ:EDAP) Sees Large Decline in Short InterestJune 2, 2025 | marketbeat.comEDAP to Present at the Jefferies Global Healthcare ConferenceMay 27, 2025 | globenewswire.comHC Wainwright Forecasts Edap Tms' Q4 Earnings (NASDAQ:EDAP)May 21, 2025 | marketbeat.comEDAP TMS S.A. (NASDAQ:EDAP) Just Reported And Analysts Have Been Cutting Their EstimatesMay 18, 2025 | finance.yahoo.comEDAP TMS S.A. (EDAP) Q1 2025 Earnings Call TranscriptMay 17, 2025 | seekingalpha.comEDAP ADRs Fall After 1Q Loss Widens More Than ExpectedMay 16, 2025 | marketwatch.comEDAP TMS First Quarter 2025 Earnings: Misses ExpectationsMay 16, 2025 | finance.yahoo.comEDAP TMS S.A. (NASDAQ:EDAP) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comEdap TMS SA (EDAP) Q1 2025 Earnings Call Highlights: Record Focal One Placements Amid Revenue ...May 16, 2025 | finance.yahoo.comEDAP TMS Earnings Call: Achievements Amid Financial ChallengesMay 15, 2025 | tipranks.comEDAP TMS downgraded to Neutral from Overweight at Piper SandlerMay 15, 2025 | msn.comEDAP TMS S.A. misses top-line and bottom-line estimates; reaffirms FY25 outlookMay 15, 2025 | seekingalpha.comEDAP Reports First Quarter 2025 Financial ResultsMay 15, 2025 | globenewswire.comEDAP TMS S.A. Q1 2025 Earnings PreviewMay 14, 2025 | seekingalpha.comEDAP to Announce First Quarter 2025 Financial Results on May 15, 2025May 1, 2025 | globenewswire.comEDAP TMS SA Announces Positive Final Results of Focal Ablation versus Radical Prostatectomy Study at AUA Annual MeetingApril 29, 2025 | quiverquant.comEDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual MeetingApril 29, 2025 | globenewswire.comEDAP TMS to launch new Focal One i robotic HIFU systemApril 24, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBLG, CTSO, EDAP, and APYX Company DescriptionsApyx Medical NASDAQ:APYX$1.92 +0.21 (+11.99%) As of 02:18 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Bone Biologics NASDAQ:BBLG$5.87 +0.57 (+10.74%) As of 02:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.Cytosorbents NASDAQ:CTSO$1.18 +0.02 (+1.38%) As of 02:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.EDAP TMS NASDAQ:EDAP$1.70 +0.01 (+0.29%) As of 02:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Dan Ives Just Unveiled His AI ETF—Does It Live Up to the Hype? Intel's Turnaround Strategy Shifts From Planning to Attack Mode Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
